![Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients | Circulation Research Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients | Circulation Research](https://www.ahajournals.org/cms/asset/725ffe87-78cf-4ed1-b2e7-234091222c20/14ff3.jpeg)
Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients | Circulation Research
![CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure - McMurray - 2011 - European Journal of Heart Failure - CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure - McMurray - 2011 - European Journal of Heart Failure -](https://onlinelibrary.wiley.com/cms/asset/279e4cbb-2e49-4698-afa8-ad021560ba3b/ejhfhfr093-fig-0001-m.jpg)
CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure - McMurray - 2011 - European Journal of Heart Failure -
Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy | PLOS ONE
![Novel RAAS agonists and antagonists: clinical applications and controversies | Nature Reviews Endocrinology Novel RAAS agonists and antagonists: clinical applications and controversies | Nature Reviews Endocrinology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrendo.2015.6/MediaObjects/41574_2015_Article_BFnrendo20156_Fig1_HTML.jpg)
Novel RAAS agonists and antagonists: clinical applications and controversies | Nature Reviews Endocrinology
![Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet](https://www.thelancet.com/cms/attachment/92c78bdc-c776-4547-8c9f-25d568de4172/gr1_lrg.gif)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet
![Diagrammatic representation of the hypothesis that spironolactone may... | Download Scientific Diagram Diagrammatic representation of the hypothesis that spironolactone may... | Download Scientific Diagram](https://www.researchgate.net/publication/347865091/figure/fig1/AS:997715802615808@1614885392277/Diagrammatic-representation-of-the-hypothesis-that-spironolactone-may-have-benefits-over.png)
Diagrammatic representation of the hypothesis that spironolactone may... | Download Scientific Diagram
![Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK](https://assets.digital.cabinet-office.gov.uk/media/56c23dc1ed915d10ba000025/Feb_2016_DSU.png)
Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK
![Addressing heart failure in primary care: Part 2 – Initiating and escalating treatment for heart failure - bpacnz Addressing heart failure in primary care: Part 2 – Initiating and escalating treatment for heart failure - bpacnz](https://bpac.org.nz/2022/img/HF-part2-fig1.png)
Addressing heart failure in primary care: Part 2 – Initiating and escalating treatment for heart failure - bpacnz
![Pharmaceuticals | Free Full-Text | Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals | Free Full-Text | Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-03-00001/article_deploy/html/images/pharmaceuticals-03-00001-g001-1024.png)
Pharmaceuticals | Free Full-Text | Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
![Structures of ACE inhibitor Enalapril, MR antagonists Spironolactone... | Download Scientific Diagram Structures of ACE inhibitor Enalapril, MR antagonists Spironolactone... | Download Scientific Diagram](https://www.researchgate.net/profile/Qingzhong-Hu/publication/232975585/figure/fig18/AS:341774955499543@1458496908014/Structures-of-ACE-inhibitor-Enalapril-MR-antagonists-Spironolactone-and-Eplerenone_Q640.jpg)
Structures of ACE inhibitor Enalapril, MR antagonists Spironolactone... | Download Scientific Diagram
![Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease | Critical Care | Full Text Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13054-020-03055-6/MediaObjects/13054_2020_3055_Fig1_HTML.png)